Shares of Lupin Thursday fell by over 4 per cent after the drug maker reported a 41.5 per cent decline in its consolidated net profit for the second quarter ended September 2018.
The stock dropped 4.13 per cent to end at Rs 852.20 on the BSE. Intra-day, it declined 4.49 per cent to Rs 849.
On the NSE, shares of the company declined by 3.89 per cent to close at Rs 851.
Lupin Wednesday reported a 41.5 per cent decline in its consolidated net profit at Rs 266 crore for the second quarter ended September 2018 as sales slipped in the US market.
The Mumbai-based company had reported a net profit of Rs 4.55 billion for the July-September period of 2017-18.
Sales for the quarter increased marginally to Rs 38.9 billion as compared to Rs 38.74 billion in the corresponding period of last fiscal, Lupin said in a regulatory filing.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)